Allakos Inc. (NASDAQ:ALLK) Short Interest Down 15.7% in December

Allakos Inc. (NASDAQ:ALLK) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 842,800 shares, a decrease of 15.7% from the November 30th total of 1,000,000 shares. Based on an average trading volume of 656,500 shares, the short-interest ratio is currently 1.3 days.

Hedge Funds Weigh In On Allakos

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALLK. Geode Capital Management LLC lifted its position in Allakos by 8.9% in the third quarter. Geode Capital Management LLC now owns 988,171 shares of the company’s stock valued at $646,000 after acquiring an additional 80,763 shares during the last quarter. RBF Capital LLC increased its position in Allakos by 45.9% during the third quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after buying an additional 160,529 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Allakos in the third quarter valued at approximately $1,143,000. FMR LLC grew its position in shares of Allakos by 14.6% during the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock worth $3,508,000 after acquiring an additional 685,623 shares during the last quarter. Finally, GSA Capital Partners LLP raised its position in Allakos by 11.9% in the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Allakos Stock Down 2.3 %

Allakos stock traded down $0.03 during trading on Monday, reaching $1.27. The stock had a trading volume of 110,464 shares, compared to its average volume of 787,023. Allakos has a 52-week low of $0.54 and a 52-week high of $3.36. The business has a 50 day moving average price of $1.16 and a 200 day moving average price of $0.90. The stock has a market cap of $113.47 million, a PE ratio of -0.63 and a beta of 0.92.

Allakos (NASDAQ:ALLK) last posted its earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. On average, equities analysts predict that Allakos will post -1.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market outperform” rating and issued a $3.00 price target on shares of Allakos in a research report on Thursday, September 26th.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.